Download the ESMO 2012 Abstract Book - Oxford Journals
24.12.2012 • Views
Share Embed Flag

Download the ESMO 2012 Abstract Book - Oxford Journals

Download the ESMO 2012 Abstract Book - Oxford Journals

Download the ESMO 2012 Abstract Book - Oxford Journals

SHOW MORE
SHOW LESS
ePAPER READ
DOWNLOAD ePAPER
oxfordjournals.org

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

START NOW

subject index<br />

ix115 (316TiP), ix116 (318O), ix116 (319O),<br />

ix117 (320PD), ix117 (321PD), ix117 (322PD),<br />

ix118 (323PD), ix118 (324PD), ix119 (325PD),<br />

ix120 (331P), ix121 (333P), ix121 (334P), ix124<br />

(343P), ix125 (347P), ix126 (348P), ix126<br />

(349P), ix34 (34IN), ix126 (350P), ix126 (351P),<br />

ix127 (352P), ix129 (359P), ix34 (35IN), ix130<br />

(362P), ix130 (363P), ix131 (365P), ix131<br />

(367P), ix133 (372P), ix133 (373P), ix133<br />

(374P), ix134 (376), ix137 (387), ix137 (388),<br />

ix139 (396), ix139 (397), ix139 (398), ix140<br />

(402), ix141 (405TiP), ix142 (406TiP), ix162<br />

(470P), ix166 (483P), ix175 (511PD), ix175<br />

(512PD), ix176 (515P), ix321 (974PD), ix57<br />

(99IN), ix25 (9IN)<br />

breast carcinoma, ix107 (287P)<br />

breast self examination, ix136 (383), ix136 (383)<br />

brentuximab vedotin, ix348 (1063O), ix353<br />

(1083P)<br />

brivanib, ix319 (966O)<br />

Brm, ix78 (186P)<br />

bronchoscopic intervention, ix517 (1608P)<br />

brown fat, ix108 (290P)<br />

BTK inhibitors, immunotoxins, ix45 (68IN)<br />

C<br />

c-kit, heat shock protein 90 inhibitor, ix538<br />

(1679P)<br />

c-kit, ix365 (1123P), ix498 (1541)<br />

c-Met inhibitor, ix67 (143PD), ix154 (444PD),<br />

ix174 (1708PD)<br />

c-MET, ix424 (1293P), ix76 (179P), ix84 (205P)<br />

c-Myc, statin, ix302 (916P)<br />

c-Myc, ix275 (832P)<br />

C-reactive protein, prognosis, ix381 (1169P)<br />

C-reactive protein, ix525 (1637)<br />

Ca 125, ix324 (983P)<br />

cabazitaxel, ix170 (497P), ix306 (931P), ix307<br />

(932P), ix307 (933P), ix312 (946), ix312 (948),<br />

ix313 (951), ix314 (953), ix314 (955), ix315<br />

(956), ix315 (958), ix316 (960), ix316 (962TiP)<br />

cachexia, ix499 (1544O), ix512 (1588P), ix161<br />

(465P)<br />

CagA, ix351 (1075P)<br />

calendula officinalis,, ix346 (1059)<br />

CAM, ix452 (1388P)<br />

cancer and chemo<strong>the</strong>rapy, ix515 (1599P)<br />

cancer associated anemia, ix504 (1561P)<br />

cancer awareness, ix380 (1166P), ix448 (1375P),<br />

ix472 (1457P)<br />

cancer burden, ix65 (137IN)<br />

cancer cachexia, ix64 (131IN), ix511 (1586P)<br />

cancer clinical trial, ix450 (1381P), ix483 (1493P)<br />

cancer genomics, ix544 (1699P)<br />

cancer immuno<strong>the</strong>rapy, ix406 (1238PD), ix536<br />

(1672P), ix268 (813P), ix301 (915P), ix313 (949)<br />

cancer informatics, ix449 (1376P)<br />

cancer nanotechnology, ix87 (217P)<br />

cancer of unknown primary origin (CUP), ix381<br />

(1169P), ix381 (1170P), ix381 (1171P)<br />

cancer patient, ix457 (1404)<br />

cancer policy, ix66 (141INIS)<br />

cancer registry implementation, ix460 (1414TiP)<br />

cancer registry, ix449 (1376P), ix175 (513PD),<br />

ix241 (725P)<br />

cancer risk, ix53 (89IN)<br />

cancer screening, ix460 (1419PD), ix470 (1452P),<br />

ix471 (1453P), ix473 (1461)<br />

cancer stem cells <strong>the</strong>rapeutics, ix160 (463P)<br />

cancer stem cells, ix71 (159P), ix72 (164), ix539<br />

(1685P), ix543 (1696P), ix86 (215P), ix136<br />

(385), ix160 (463P)<br />

cancer, ix65 (135IN), ix447 (1369P), ix456<br />

(1401P), ix458 (1408), ix459 (1412), ix476<br />

(1471P), ix478 (1477O), ix519 (1616P), ix71<br />

(161P), ix242 (729P), ix56 (98IN)<br />

capecitabine, ix128 (356P), ix129 (358P), ix138<br />

(394), ix139 (398), ix140 (399), ix187 (550P),<br />

ix193 (566P), ix200 (588P), ix234 (700P), ix240<br />

(722P), ix250 (757), ix256 (781TiP), ix257<br />

(782TiP), ix229 (683P)<br />

CAPOX, ix218 (647)<br />

carboplatin and pemetrexed, ix434 (1326)<br />

carboplatin plus paclitaxel, ix398 (1221)<br />

carboplatin, ix340 (1037P), ix397 (1218), ix409<br />

(1246P), ix151 (437TiP), ix283 (857P), ix286<br />

(867P)<br />

carcinoembryonic antigen (CEA), ix199 (583P),<br />

ix221 (659)<br />

carcinoids, ix47 (73IN)<br />

carcinoma cervix, ix328 (997P)<br />

cardiac safety, ix128 (357P), ix178 (519O)<br />

cardiac toxicity, ix113 (309)<br />

cardio-toxicity, cardio-protection, anthracyclines,<br />

echocardiography, ix539 (1682P)<br />

cardiotoxicity, ix455 (1397P)<br />

care satisfaction, ix475 (1468P)<br />

caregiver, ix343 (1047P)<br />

cargiverś burden, ix145 (415PD)<br />

castrate-resistant prostate cancer (CRPC), PSA,<br />

ix304 (923P)<br />

castrate-resistant prostate cancer (CRPC), ix296<br />

(897O), ix298 (902P), ix298 (903P), ix300<br />

(909P), ix301 (913P), ix301 (915P), ix305<br />

(927P), ix308 (934P), ix315 (958), ix316 (960),<br />

ix317 (964TiP)<br />

castrate-resistant prostate cancer, ix38 (47IN),<br />

ix296 (898PD), ix308 (936P)<br />

castration resistant prostate cancer, ix300 (911P),<br />

ix302 (917P), ix303 (921P), ix305 (926P), ix314<br />

(954), ix317 (963TiP)<br />

castration-resistant prostate cancer, ix304 (924P),<br />

ix305 (925P)<br />

catumaxomab, ix514 (1596P), ix539 (1683P),<br />

ix163 (472P), ix172 (504), ix228 (680P)<br />

caucasian patients, ix337 (1026P), ix439 (1346)<br />

CD10, ix107 (287P)<br />

CD117, ix349 (1067PD)<br />

CD133-positive blood vessels, ix146 (418PD)<br />

CD133, ix205 (604P)<br />

CD135, ix349 (1067PD)<br />

CD20, ix70 (157P)<br />

CD24, ix87 (216P)<br />

CD30+ lymphomas, ix348 (1063O)<br />

CD30 + , ix285 (861P)<br />

CD32, ix70 (157P)<br />

CD34+ stem cell mobilization and collection,<br />

ix353 (1082P), ix353 (1083P)<br />

CD40, ix529 (1650P)<br />

CD44 + /CD24-/Lin-cells, ix110 (300)<br />

CD44, ix87 (216P)<br />

2 CdA, ix352 (1076P)<br />

cediranib, ix155 (448PD), ix207 (609P)<br />

cell growth, ix88 (220P)<br />

cell-free DNA, ix73 (168O)<br />

CellSearch, ix338 (1029P), ix90 (227P)<br />

CellSearchSystem, ix489 (1512)<br />

central nerve system metastasis, ix251 (764)<br />

cervical cancer screening, ix471 (1454P), ix471<br />

(1455P)<br />

cervical cancer, ix328 (1000P), ix330 (1007), ix330<br />

(1007), ix331 (1008), ix331 (1009), ix331 (1010),<br />

ix475 (1466P), ix524 (1632), ix22 (3IN), ix327<br />

(996P), ix328 (998P), ix328 (999P)<br />

cetuximab resistance, ix67 (143PD), ix530<br />

(1651P), ix42 (59IN), ix334 (1018O)<br />

cetuximab, ix340 (1036P), ix342 (1044P), ix345<br />

(1052), ix372 (1144), ix396 (1213), ix396 (1216),<br />

ix417 (1272P), ix528 (1644PD), ix87 (218P),<br />

ix93 (237), ix178 (520O), ix180 (526PD), ix183<br />

(535P), ix190 (557P), ix191 (561P), ix192<br />

(563P), ix194 (568P), ix196 (572P), ix198<br />

(580P), ix199 (582P), ix206 (606P), ix206<br />

(608P), ix213 (630), ix217 (643), ix233 (696P)<br />

cfDNA, ix533 (1664P)<br />

CH5424802, ix153 (441O)<br />

Annals of Oncology<br />

challenges, ix65 (135IN)<br />

Charson comorbidity index, ix349 (1065O)<br />

checklist, ix524 (1634)<br />

checkpoint protein biomarker antibody, ix46<br />

(71IN)<br />

chemo-radio<strong>the</strong>rapy, ix342 (1045P), ix206 (608P),<br />

ix208 (612P), ix225 (671P), ix328 (999P)<br />

chemo-resistance, ix159 (458P)<br />

chemoembolisation, ix35 (40IN), ix254 (772)<br />

chemokine ligand 2, ix277 (838P)<br />

chemomodulation, ix370 (1135P)<br />

chemoprevention, ix34 (36IN)<br />

chemoradiation, ix330 (1007), ix215 (638)<br />

chemoradio<strong>the</strong>rapy, ix520 (1620), ix207 (609P),<br />

ix215 (637), ix226 (673P), ix237 (711P)<br />

chemoresistance, ix370 (1135P)<br />

chemosensitivity, ix429 (1308P)<br />

chemo<strong>the</strong>rapeutic drugs, ix38 (47IN)<br />

chemo<strong>the</strong>rapy combination, ix371 (1138P), ix138<br />

(391), ix166 (484P)<br />

chemo<strong>the</strong>rapy holiday, ix181 (528PD)<br />

chemo<strong>the</strong>rapy induced peripheral neuropathy,<br />

ix521 (1622)<br />

chemo<strong>the</strong>rapy regimens, ix214 (634), ix320<br />

(972PD)<br />

chemo<strong>the</strong>rapy toxicity, ix452 (1386P), ix511<br />

(1587P)<br />

chemo<strong>the</strong>rapy-induced anaemia, ix504 (1563P),<br />

ix506 (1568P), ix506 (1569P), ix523 (1627)<br />

chemo<strong>the</strong>rapy-induced anemia, ix505 (1565P),<br />

ix505 (1567P)<br />

chemo<strong>the</strong>rapy-induced mucositis, ix163 (473P)<br />

chemo<strong>the</strong>rapy-induced nausea and vomiting,<br />

ix509 (1579P)<br />

chemo<strong>the</strong>rapy-induced neutropenia, ix499<br />

(1547PD), ix500 (1548PD)<br />

chemo<strong>the</strong>rapy-induced oral mucositis, ix514<br />

(1595P)<br />

chemo<strong>the</strong>rapy-induced peripheral neurotoxicity,<br />

ix512 (1590P), ix513 (1591P)<br />

chemo<strong>the</strong>rapy-naive, ix294 (894O)<br />

chemo<strong>the</strong>rapy, ix331 (1010), ix332 (1013), ix340<br />

(1036P), ix342 (1044P), ix352 (1076P), ix378<br />

(1159P), ix378 (1160P), ix378 (1161P), ix381<br />

(1171P), ix391 (1199P), ix62 (121IN), ix398<br />

(1222), ix398 (1223), ix408 (1243P), ix408<br />

(1244P), ix411 (1254P), ix427 (1301P), ix429<br />

(1306P), ix429 (1308P), ix435 (1331), ix440<br />

(1348), ix443 (1357), ix447 (1369P), ix457<br />

(1406), ix459 (1411), ix459 (1412), ix484<br />

(1496P), ix485 (1500P), ix493 (1525P), ix496<br />

(1536P), ix497 (1537P), ix500 (1549PD), ix503<br />

(1558P), ix504 (1562P), ix513 (1592P), ix515<br />

(1598P), ix27 (15IN), ix518 (1609P), ix518<br />

(1611P), ix521 (1623), ix523 (1628), ix526<br />

(1640), ix72 (164), ix75 (175PD), ix85 (209P),<br />

ix29 (21IN), ix31 (24IN), ix107 (288P), ix113<br />

(309), ix117 (321PD), ix122 (336P), ix133<br />

(373P), ix37 (45IN), ix164 (477P), ix171 (500P),<br />

ix172 (504), ix194 (569P), ix208 (614P), ix212<br />

(628), ix218 (647), ix218 (648), ix222 (661),<br />

ix231 (690P), ix242 (730P), ix242 (731P), ix244<br />

(736P), ix250 (756), ix250 (757), ix256<br />

(780TiP), ix260 (788O), ix264 (799P), ix265<br />

(803P), ix307 (932P), ix56 (96IN), ix325 (985P),<br />

ix327 (995P)<br />

chest CT screening, ix469 (1447PD)<br />

chest wall irradiation, ix114 (314)<br />

chest wall, ix130 (363P), ix131 (367P)<br />

Child-Pugh status, ix244 (736P)<br />

children, ix359 (1104), ix517 (1606P)<br />

chimeric anti-meso<strong>the</strong>lin monoclonal antibody,<br />

ix493 (1522PD)<br />

China, ix501 (1552P), ix114 (313)<br />

Chinese, ix282 (851P)<br />

chk1, ix42 (61IN)<br />

chlorhexidine, ix522 (1626)<br />

choi response criteria, ix379 (1163P)<br />

ix588 | subject index Volume 23 | Supplement 9 | September <strong>2012</strong>

logo

products

Resources

Company

Terms of service
Privacy policy
Cookie policy
Cookie settings
Imprint
Change language
Made with love in Switzerland
© 2024 Yumpu.com all rights reserved

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!